CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS [Yahoo! Finance]
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI)
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
casipharmaceuticals.com/investor-relations
Company Research
Source: Yahoo! Finance
and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023 , and provided an update on key highlights for 2023. CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA ® , 33% lower than the same period in 2022. The 2023 full-year revenue of $34 million reflects an 11% of decrease compared to 2022. Wei-Wu He , Ph.D., CASI's Chairman and Chief Executive Officer, said "CASI's team has navigated our business through a challenging external environment. We have successfully brought the second commercial product FOLOTYN ® to China market as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). We will continue to strengthen the commercial franchise throughout 2024 and beyond. At the same time, our regulatory and development team made significant pipeline advancements." Dr. He continued, "Advancement, development, and commercialization of the pi
Show less
Read more
Impact Snapshot
Event Time:
CASI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CASI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CASI alerts
High impacting CASI Pharmaceuticals, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CASI
News
- Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI) [Yahoo! Finance]Yahoo! Finance
- BioInvent International AB: Interim Report January-March 2024 [Yahoo! Finance]Yahoo! Finance
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS [Yahoo! Finance]Yahoo! Finance
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASPR Newswire
- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CASI
Earnings
- 11/14/23 - Beat
CASI
Sec Filings
- 4/8/24 - Form 6-K
- 3/28/24 - Form 6-K
- 3/28/24 - Form 20-F
- CASI's page on the SEC website